Edge Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Edge Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100	Closed	-$3K	–	942
2018 Q1	$3K	Hold	100	–	–	﹤0.01%	784
2017 Q4	$4K	Hold	100	–	–	﹤0.01%	813
2017 Q3	$5K	Hold	100	–	–	﹤0.01%	763
2017 Q2	$5K	Hold	100	–	–	﹤0.01%	819
2017 Q1	$3K	Hold	100	–	–	﹤0.01%	858
2016 Q4	$2K	Buy	+100	New	+$1.95K	﹤0.01%	790

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Edge Advisors's PTLA Position: Q2 2018 in Review

Edge Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 100 shares — an estimated $3K sold.

Edge Advisors first reported a position in PTLA in Q4 2016 and held it in 6 quarters. The position peaked at $5K in Q3 2017. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

Edge Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Edge Advisors sold 100 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $3K.
Edge Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2016 and held it in 6 quarters.
Edge Advisors's Portola Pharmaceuticals, Inc. position peaked at $5K in Q3 2017.
204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.